Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 286

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 286
---
 | NYSE:DGX      |     |      19,250 |   |     |      9,252 |     |     1,773 |   |
| Exact Sciences Corporation     |     | NASDAQCM:EXAS |     |      12,877 |   |     |      2,500 |     |      (102 | ) |
| Eurofins Scientific SE         |     | ENXTPA:ERF    |     |      15,134 |   |     |      7,045 |     |     1,284 |   |
| Digital Healthcare Platforms   |     |               |     |             |   |     |            |     |           |   |
| American Well Corporation      |     | NYSE:AMWL     |     |         (71 | ) |     |        259 |     |      (226 | ) |
| Sharecare, Inc.                |     | NASDAQGS:SHCR |     |         266 |   |     |        442 |     |       (94 | ) |

____________ Notes:- (1)Figures in millions. (2)Based on closing share price as of March 13, 2024. •consultation with APx’s management and its legal counsel and review of key management employment agreements; •review of historical financial performance of the Company (including audited and unaudited financial statements, income statements, balance sheets, statement of operations and statements of cash flow); •confirmatory financial due diligence, including comparing financial performance metrics and other financial information of the Company (primarily its budgets, unit costs and pricing, and historical balance sheets) with other companies in the healthcare and technology sectors. While this comparable company analysis was used to subjectively evaluate the Business Combination, these metrics were not used to quantitatively arrive at the proposed valuation of OmnigenicsAI. In approving the Business Combination, the APx Board was not provided with projections for the Company or Heritas Argentina and determined not to obtain a fairness opinion. The officers and directors of APx have substantial experience in evaluating the operating and financial merits of companies from a wide range of industries given their diverse backgrounds in operational management, investments, technology and financial management and analysis and concluded that their experience and background enabled them to make the necessary analyses and determinations regarding the Business Combination. Mr. Bransfield served as director and Chief Executive Officer of Union Acquisition Corp, and Union Acquisition Corp. II, leading the companies through